|Print Page Close Window|
MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.Read More
Recent Press Releases
11/12/18MyoKardia Presents Preclinical Evidence of Mavacamten’s Novel Effect on Diastolic Compliance at the 2018 American Heart Association Scientific Sessions
NASDAQ GS | MYOK (Common Stock)
$59.19 + 2.08
10/26/184:00 p.m. ETData provided by Nasdaq. Minimum 15 minutes delayed.
There are currently no events scheduled.